X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES AUROBINDO PHARMA VENUS REMEDIES/
AUROBINDO PHARMA
 
P/E (TTM) x -842.8 18.0 - View Chart
P/BV x 0.2 5.9 4.2% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
AUROBINDO PHARMA
Mar-16
VENUS REMEDIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2181,541 14.2%   
Low Rs82582 14.1%   
Sales per share (Unadj.) Rs365.6237.5 154.0%  
Earnings per share (Unadj.) Rs1.533.9 4.4%  
Cash flow per share (Unadj.) Rs37.940.6 93.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs382.5120.6 317.2%  
Shares outstanding (eoy) m11.44585.17 2.0%   
Bonus/Rights/Conversions -PREF-  
Price / Sales ratio x0.44.5 9.2%   
Avg P/E ratio x101.031.3 322.3%  
P/CF ratio (eoy) x4.026.2 15.1%  
Price / Book Value ratio x0.48.8 4.5%  
Dividend payout %07.4 0.0%   
Avg Mkt Cap Rs m1,717621,041 0.3%   
No. of employees `0001.013.3 7.7%   
Total wages/salary Rs m32415,508 2.1%   
Avg. sales/employee Rs Th4,100.710,457.6 39.2%   
Avg. wages/employee Rs Th318.01,167.1 27.3%   
Avg. net profit/employee Rs Th16.71,491.6 1.1%   
INCOME DATA
Net Sales Rs m4,183138,961 3.0%  
Other income Rs m201,663 1.2%   
Total revenues Rs m4,203140,624 3.0%   
Gross profit Rs m81232,056 2.5%  
Depreciation Rs m4173,926 10.6%   
Interest Rs m3802,568 14.8%   
Profit before tax Rs m3527,225 0.1%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m187,444 0.2%   
Profit after tax Rs m1719,820 0.1%  
Gross profit margin %19.423.1 84.1%  
Effective tax rate %51.627.3 188.6%   
Net profit margin %0.414.3 2.8%  
BALANCE SHEET DATA
Current assets Rs m2,771100,015 2.8%   
Current liabilities Rs m1,93174,759 2.6%   
Net working cap to sales %20.118.2 110.4%  
Current ratio x1.41.3 107.2%  
Inventory Days Days125107 116.4%  
Debtors Days Days54110 49.0%  
Net fixed assets Rs m5,32852,350 10.2%   
Share capital Rs m114585 19.5%   
"Free" reserves Rs m4,17767,707 6.2%   
Net worth Rs m4,37670,567 6.2%   
Long term debt Rs m1,9118,472 22.6%   
Total assets Rs m8,428156,994 5.4%  
Interest coverage x1.111.6 9.4%   
Debt to equity ratio x0.40.1 363.6%  
Sales to assets ratio x0.50.9 56.1%   
Return on assets %4.714.3 33.0%  
Return on equity %0.428.1 1.4%  
Return on capital %6.637.7 17.5%  
Exports to sales %051.0 0.0%   
Imports to sales %20.518.8 108.9%   
Exports (fob) Rs mNA70,927 0.0%   
Imports (cif) Rs m85826,193 3.3%   
Fx inflow Rs m071,015 0.0%   
Fx outflow Rs m85828,799 3.0%   
Net fx Rs m-85842,216 -2.0%   
CASH FLOW
From Operations Rs m46917,596 2.7%  
From Investments Rs m29-13,801 -0.2%  
From Financial Activity Rs m-464-198 233.7%  
Net Cashflow Rs m353,597 1.0%  

Share Holding

Indian Promoters % 32.9 54.1 60.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.0 2.3%  
FIIs % 0.6 27.7 2.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.2 651.0%  
Shareholders   20,121 69,601 28.9%  
Pledged promoter(s) holding % 36.4 8.6 424.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   GLENMARK PHARMA  FULFORD INDIA  WYETH LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Tata Stocks in Focus(09:30 am)

Asian stock indices are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.13% while the Hang Seng is down 0.54%. The Shanghai Composite is trading down by 0.02%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 24, 2017 11:13 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS